Editor’s Note: David Fox is a partner at Kirkland & Ellis LLP, focusing on complex mergers and acquisitions as a member of that firm’s Corporate Group. This post is based on a Kirkland & Ellis
M&A Update by Mr. Fox and
Daniel Wolf. This post is part of the
Delaware law series, which is cosponsored by the Forum and Corporation Service Company; links to other posts in the series are available
here.
The current takeover battle between Airgas and Air Products highlights one of the key areas of uncertainty in Delaware law today—the continued vitality of the “just say no” defense to unsolicited advances. Stated simply, if upheld, the “just say no” defense allows the board of directors of a target company to combine a refusal to negotiate and an unwillingness to waive structural defenses such as a poison pill or its less-effective statutory counterpart, Section 203 of the Delaware corporate code, to frustrate advances from an unwanted suitor. The defense is unique to the U.S. market— by comparison to the swift resolution of the recent Cadbury/Kraft hostile offer mandated by UK takeover rules, the defense can result in protracted battles that last for months, and sometimes years, oftentimes despite support for an offer from target shareholders.
Despite its popularity in the public (well, the dealmakers’) imagination, the “just say no” defense has a somewhat limited judicial pedigree. The case most often cited as establishing the validity of the defense is a 1995 Federal decision applying Delaware law to the defense by Wallace Computer against a hostile bid from Moore. In that case, the court upheld the refusal by Wallace’s board to redeem a pre-existing poison pill in the face of a non-coercive premium tender offer that was accepted by nearly 75% of Wallace’s shareholders. This ruling was seemingly inconsistent with the holdings in two 1988 Delaware Chancery decisions (Interco and Grand Metro) where redemption of a poison pill was mandated. The court held in the Wallace case that the mere refusal to redeem a historical poison pill can be viewed as defensive, thereby triggering the enhanced scrutiny of Unocal to the board’s decision. However, the court found that the board’s decision satisfied the two requirements of the Unocal test of defensive measures—the board’s good faith and sound investigation showed reasonable grounds for the board’s belief that a danger to corporate policy and effectiveness existed (i.e., the danger that shareholders, tempted by the premium, would tender at an inadequate price in ignorance of the true value of the target) and the retention of the poison pill, even beyond the period necessary to formulate an alternative plan to maximize shareholder value, was reasonable and proportionate to the danger posed. As such, the board’s defense was entitled to the presumptions of the “business judgment rule” and would not be second-guessed by the court.
…continue reading: “No Mas” to “Just Say No”?